HC Wainwright Has Bullish Estimate for BCTX Q2 Earnings

BriaCell Therapeutics Corp. (NASDAQ:BCTX) – Analysts at HC Wainwright upped their Q2 2025 earnings per share estimates for shares of BriaCell Therapeutics in a research note issued to investors on Monday, February 3rd. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($1.94) per share for the quarter, up from their previous estimate of ($4.05). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($15.14) per share. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($2.45) EPS, FY2026 earnings at ($1.47) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.69) EPS and FY2029 earnings at ($0.24) EPS.

BriaCell Therapeutics Stock Performance

Shares of BCTX opened at $4.48 on Wednesday. The firm’s 50-day simple moving average is $8.79 and its 200 day simple moving average is $10.33. The firm has a market cap of $13.22 million, a P/E ratio of -0.34 and a beta of 1.59. BriaCell Therapeutics has a 52 week low of $3.92 and a 52 week high of $65.25.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings data on Monday, December 16th. The company reported ($3.30) EPS for the quarter, missing the consensus estimate of ($1.20) by ($2.10).

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. increased its holdings in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 37.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 110,000 shares of the company’s stock after acquiring an additional 30,000 shares during the quarter. Vontobel Holding Ltd. owned about 0.25% of BriaCell Therapeutics worth $62,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.